Biotech Values

[DewDiligence]

IDIX—Would another pharma be willing to shell out billions and have the deal blow up like BMY did?

NVS—who had the right of first negotiation—already passed on IDX184. Moreover, yesterday’s re-alignment of the NVS-IDIX relationship (#msg-78051775) is tantamount to a NVS vote of no-confidence in IDIX’s general prowess in HCV.